Natural ovulation versus programmed regimens before frozen embryo transfer in ovulatory women: multicentre, randomised clinical trial.

The introduction cites numerous prior studies and meta-analyses that established the controversy about optimal endometrial preparation regimens and the limitations of previous trials in evaluating obstetric complications. The hypothesis that a natural ovulation regimen would improve the chance of a healthy live birth and lower the risk of pre-eclampsia or eclampsia is clearly stated and logically follows from the cited evidence. The paper acknowledges that prior randomized trials were not sufficiently powered to capture differences in obstetric and neonatal complications, and that observational studies warranted confirmation through large randomized trials.

Randomization was stratified by study site using block randomisation with variable block sizes of 2, 4, and 6, and the sequence was generated by a data coordinating centre, which is adequate. The unit of randomization is the patient. Assessor blinding was implemented (obstetricians and paediatricians blinded to treatment allocation). An a priori power analysis was performed for both primary outcomes, with a clear effect size, alpha, and power stated. Inclusion and exclusion criteria are explicitly listed. The trial was registered (ChiCTR2200057990). Protocol deviations are reported. However, the paper does not describe a formal data safety monitoring board or explicit stopping rules, which is not a core item in the checklist. The study design is a pragmatic multicentre trial; independent replication is not applicable for a single pivotal trial of this nature.

The paper provides a detailed baseline characteristics table (Table 1) including age, BMI, parity, infertility history, blood pressure, and other relevant clinical variables. Sex is implicitly female (ovulatory women). Age and health status (BMI, blood pressure, chronic hypertension) are reported. Species/strain and housing conditions are not applicable for human trials. Demographics such as age and BMI are thoroughly reported; race/ethnicity is not reported, which may be relevant as the study was conducted in China, but this is a common limitation and does not warrant a fail given the other comprehensive reporting.

The paper states: 'This trial was approved by the ethics committee of Hospital for Reproductive Medicine Affiliated to Shandong University (ID:2022-89) and all participating centres.' This provides a named body and protocol number, which is adequate. It also states 'All patients provided written informed consent.' The paper includes a statement of compliance with ICMJE disclosure and transparency. Regulatory compliance is implied but not explicitly stated (e.g., Declaration of Helsinki); however, given the named ethics approval and consent, the overall ethical reporting is adequate.

This is a clinical trial of a procedure, not a bench study. The investigational products (hormonal medications) are named with manufacturer: Progynova (Delpharm Lille SAS), Crinone (Merck Serono), Utrogestan (Besins Healthcare), Duphaston (Abbott). Doses and regimens are described. The software (SAS version 9.4) is identified. Cell line authentication, mycoplasma testing, antibodies, and organisms are not applicable. The trial is scored because it uses investigational products; these are adequately identified for a clinical trial context (vendor and formulation are given; lot numbers are not required).

The paper names specific tests (χ² test, Fisher's test, Student's t-test, Wilcoxon rank-sum test, Cochran-Mantel-Haenszel test). Assumptions were verified by visual inspection of histograms and Kolmogorov-Smirnov test (for normality). Exact p-values are reported for primary outcomes (e.g., P=0.49, P=0.02). Effect sizes (absolute differences, relative ratios) with 95% confidence intervals are reported. Software is identified (SAS 9.4). Data presentation includes per-group n and percentages in tables, and a CONSORT flow diagram is referenced. For mathematical plausibility, many comparisons are reported with cell counts; no obvious arithmetic errors are apparent. One minor issue: the paper does not explicitly state a handling plan for outliers or missing data beyond the ITT principle (patients lost to follow-up categorized as no live birth), which is adequate for the primary analysis.

The data availability statement explicitly states: 'The data underlying the findings in this paper are openly and publicly available at https://github.com/hepingzhangyale/EndometrialPreparation-/tree/main .' This is a concrete route (a repository with a URL). Additionally, 'The code used to analyse the data in the paper can be found in the supplemental files.' Although GitHub is not a permanent, persistent-identifier repository (like Zenodo with a DOI), the statement is concrete and meets the criteria for adequacy in this field. The code is shared in supplemental files. Repository deposit and accession numbers are covered by the GitHub link; no additional accession numbers are needed. The study uses patient-level data which are deposited openly (de-identified).

The methods are detailed enough for replication (full protocols for both regimens, monitoring, embryo transfer). The trial is registered (ChiCTR2200057990). A CONSORT flow diagram is referenced. All primary and secondary outcomes are reported transparently, including non-significant results. Limitations are discussed: protocol deviations, lack of mechanistic measurements, variability in luteal phase support, and restricted eligibility criteria. Conclusions are proportional: the paper does not overclaim and correctly notes that the results should be confirmed in other populations. Funding sources and grant numbers are listed, and a conflict of interest statement is provided.